Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 316 participants.

Also called NCT06091176

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 316 participants (planned count) (from the registry)
Sponsor
Newel Health SRL (from the registry)
Registry
  • NCT NCT06091176
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06091176. Randomized; double masking; primary purpose treatment. Start 2024-11-01 (anticipated); primary completion 2025-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension
Condition
Essential Hypertension
Condition
Primary Hypertension
Intervention (Device)
Amicomed®
Intervention (Device)
Digital Placebo
Intervention (Other)
Usual Care
Lead sponsor
Newel Health SRL (class: industry)

Record details

Record id
cardio:ct-nct06091176
Content hash
4e6a9e5e807a34862714eeacbba369d63eb7ddf5aec86723070318b0301a94b2